Zoetis to acquire Nexvet Biopharma

Share This:
Search for similar articles by keyword: [Biotechnology]

PARSIPPANY, NJ – Zoetis Inc., through a wholly owned subsidiary named Zoetis Bidco, will purchase Tullamore, Ireland-based Nexvet Biopharma, a leading developer of pain management therapies for dogs and cats. The transaction is valued at $85 million, or $6.72 per share.

Nexvet is a biologic therapeutics company with monoclonal antibody (mAb) therapies under development for companion animals in pain and other therapeutic areas. The company has research and development operations in Melbourne, Australia, a manufacturing facility in Tullamore, and an office in San Francisco.

“This acquisition is a strategic fit that brings to Zoetis an R&D organization that shares our commitment to industry-leading innovation,” said Dr. Alejandro Bernal, executive vice president and group president, Strategy, Commercial and Business Development at Zoetis. “It will strengthen our R&D pipeline in monoclonal antibodies and help sustain our category leadership in chronic pain management for companion animals, which is an area poised for innovation with new mAb therapies. The transaction demonstrates how we continue to invest to drive innovation and future growth.”

The global market for therapies to treat chronic pain in companion animals is valued at an estimated $400 million a year, according to Zoetis. If approved, Nexvet’s product ranevetmab, a mAb targeting nerve-growth factor (NGF) for treatment of chronic pain associated with osteoarthritis in dogs could be the companion animal industry’s first monoclonal antibody therapy administered monthly by injection for chronic pain, the company said.

Nexvet also is developing frunevetmab, a monoclonal antibody targeting NGF to treat chronic pain associated with osteoarthritis in cats, which represents a new opportunity in feline pain that is underserved today, Zoetis noted.

Comment on this Article
We welcome your thoughtful comments. Please comply with our Community rules.



The views expressed in the comments section of Meat and Poultry News do not reflect those of Meat and Poultry News or its parent company, Sosland Publishing Co., Kansas City, Mo. Concern regarding a specific comment may be registered with the Editor by clicking the Report Abuse link.